Net income at United Therapeutics Corp.    surged more than four-fold in its latest quarter as sales rose and the Silver Spring pharmaceutical firm curbed expenses.

United Therapeutics (NASDAQ: UTHR) maintained the sales growth momentum of its line-up of cardiopulmonary hypertension medicines in the fourth quarter. Total revenue increased 19 percent to $195.2 million.

To read the full, original article click on this link: United Therapeutics net income jumps to $43.2M - Washington Business Journal